Category: angel investors

Fermah, a NYC-based, developer of proof generation layer platform intended to offer marketplace support to its users. The company’s platform manages supply and demand size with the help of machines such as GPUs and FPGAs, enabling users to get cheap, fast, and reliable ZK-proof generation.

Fermah was funded $5.2 million led by a16z CSX fund and Lemniscap with participation from Bankless Ventures, Longhash Ventures, P-OPS team, Public Works, ZK Validator, Lambda Class, Daedalus, Zero DAO, Velocity Capital, and Daemon Ventures, as well as angel investors including former Coinbase CTO and a16z. The company intends to use the funds to accelerate product development and team expansion.

Fermah’s mission is to abstract away the complexity involved in creating and using ZK proofs, making them accessible to developers and businesses without requiring deep cryptographic knowledge. By doing so, Fermah aims to unlock new use cases for ZK proofs across various industries, from decentralized finance (DeFi) to secure data sharing in enterprise environments.

The core value proposition of Fermah’s platform lies in its user-friendly interface and developer tools that simplify ZK proof generation. Instead of writing intricate cryptographic code, developers can use Fermah’s APIs and tools to easily integrate ZK proofs into their applications. This abstraction layer reduces both the time and expertise needed to deploy secure and privacy-preserving solutions, opening the doors for wider adoption.

Fermah also plans to invest in community-building efforts, providing resources and support for developers interested in using ZK proofs in their projects. By fostering an ecosystem around their platform, Fermah aims to drive innovation in how ZK proofs are used across industries.

The significance of Fermah’s platform extends beyond simply making ZK proofs easier to generate. It represents a broader trend of abstracting complex technologies to make them more accessible and usable by the developer community. In much the same way that cloud providers like AWS abstract the complexity of infrastructure management, Fermah is doing the same for cryptography with its ZK proof tools.

This strategic positioning could make Fermah a key player in the future of decentralized technology. As industries continue to shift towards privacy-centric solutions, the demand for technologies that can protect user data while ensuring security will only grow. Fermah’s platform could serve as the foundational layer for a new wave of applications built on ZK proofs.

With fresh capital in hand, Fermah is poised to accelerate its growth trajectory. In the short term, the company plans to enhance its platform by adding new features that further streamline ZK proof generation. Long-term, Fermah aims to expand its customer base by targeting industries beyond blockchain, including finance, healthcare, and government sectors where privacy-preserving technologies are in high demand.

Fermah’s success in simplifying ZK proofs could also inspire other startups and tech companies to explore similar strategies, potentially leading to broader adoption of privacy-focused technologies across the tech landscape.

By: K. Tagura

Who we are: Funded.com is a platform that is A+ BBB accredited over 10+ years. Access our network of Angel Investors, Venture Capital or Lenders. Let us professionally write your Business Plan.

Candid Therapeutics, a San Diego, CA-based biotechnology company, is steadfast in its mission to develop potentially transformative drugs that address autoimmune diseases. Their unwavering dedication is a testament to their commitment and reliability in the field.

Candid Therapeutics was funded $370 million, propelling the company toward developing breakthrough therapies targeting autoimmune diseases. This substantial investment marks a pivotal moment in Candid’s mission to revolutionize treatment for patients with debilitating autoimmune conditions. With this financial boost, the company aims to accelerate its clinical trials and bring life-changing therapies to market.

Candid Therapeutics’ innovative approach is at the forefront of the industry, utilizing cutting-edge technologies such as gene editing and advanced biologics. This novel strategy, designed to reset the immune system rather than suppress it, could significantly reduce the need for lifelong medication and minimize the side effects associated with traditional therapies, such as immunosuppressants.

The round was co-led by Venrock Healthcare Capital Partners, Fairmount, TCGX, and venBio Partners. Other healthcare angel investors included Foresite Capital, Third Rock Ventures, Fidelity Management & Research Company, Samsara BioCapital, Qiming Venture Partners USA, OrbiMed, Boxer Capital, Redmile Group, Vida Ventures, Two River, Franklin Templeton, LifeSci Venture Partners, Mirae Asset Capital Life Science, Polaris Innovation Fund, Soleus Capital and others.

Candid Therapeutics is currently focusing its efforts on three primary autoimmune diseases: type 1 diabetes, inflammatory bowel disease (IBD), and multiple sclerosis (MS). Each condition represents a significant unmet need in the medical community, with millions of patients worldwide seeking more effective treatments.

With the new funding, Candid Therapeutics plans to initiate several clinical trials over the next 12 to 18 months. The company works closely with regulatory agencies to ensure swift approval and efficient trial processes. Early-stage trials have shown promising results, particularly in their type 1 diabetes and MS programs, where patients demonstrated a marked improvement in disease progression and symptom reduction.

Candid Therapeutics’ funding success reflects a growing investment trend in biotechnology companies focused on autoimmune diseases. As the prevalence of these conditions continues to rise, there is increasing demand for new treatments that offer more than symptom management. Investors recognize the potential for innovative therapies to disrupt the current treatment landscape and provide significant returns, both financially and in terms of patient outcomes.

The biotech industry is eagerly watching Candid Therapeutics as it moves toward clinical trials and potential FDA approvals. If successful, the company’s therapies could not only represent a new frontier but also a beacon of hope in autoimmune disease treatment, offering optimism to millions of patients worldwide.

By: K. Tagura

Who we are: Funded.com is a platform that is A+ BBB accredited over 10+ years. Access our network of Angel Investors, Venture Capital or Lenders. Let us professionally write your Business Plan.

Moveo.AI, a NYC-based developer, stands out with its unique conversational AI technology agent. This agent, designed to enhance customer service, utilizes proprietary large language models trained on historical and real-time data. These models enable the creation of self-improving generative artificial intelligence agents, empowering enterprises to elevate customer experiences and operational efficiency through the implementation of virtual agents.

Moveo.AI’s recent funding of $2.6 million, led by Eleven Ventures angel investors with participation from Uni.Fund and Charge.vc, is a strategic move. It underscores the growing confidence in Moveo.AI’s potential to revolutionize AI-driven solutions across various industries.

Moveo.AI’s current achievements are not just milestones, but strategic investments aimed at bolstering its AI technology. The company plans to allocate significant funds to enhance its proprietary AI algorithms and expand its suite of AI-driven products and services, demonstrating its commitment to continuous innovation.

In an industry where continuous innovation is crucial, Moveo.AI’s focus on refining its technology will likely set it apart from competitors. The company has been known for its cutting-edge AI tools that provide businesses with advanced analytics, automation, and decision-making capabilities. With this new funding, Moveo.AI aims to push the boundaries of what its AI technology can achieve, offering even more sophisticated solutions to its growing client base.

Moveo.AI’s expansion strategy is not just about increasing its physical footprint in these regions, but also about tailoring its AI solutions to meet the specific needs of local markets. This strategic approach will enable the company to tap into new opportunities, expand its customer base, and build stronger relationships with businesses worldwide, instilling confidence in its future growth.

Moveo.AI’s expansion comes at a strategic time, aligning with the global surge in demand for AI solutions. This foresight positions the company to meet the needs of businesses across various sectors, from finance and healthcare to retail and logistics, who are increasingly turning to AI to streamline operations, enhance customer experiences, and gain a competitive edge.

Moveo.AI’s solutions, including AI-powered chatbots, predictive analytics, and process automation tools, have already gained significant traction among businesses seeking to leverage AI for growth. With the new funding, Moveo.AI is well-positioned to scale its operations and meet the rising demand for AI-driven innovations, further solidifying its market position.

As part of its expansion strategy, Moveo.AI is also looking to strengthen partnerships with key players in the tech industry. The company has a history of collaborating with other technology firms to integrate its AI solutions into broader tech ecosystems. These partnerships enhance the capabilities of Moveo.AI’s products and help the company reach a wider audience.

The recent funding round’s success can be attributed to the strong leadership of Moveo.AI’s executive team, which has been instrumental in guiding the company’s growth and development. The team’s vision for the future involves advancing AI technology and ensuring that Moveo.AI remains at the forefront of the AI industry.

Looking ahead, Moveo.AI is committed to maintaining its focus on research and development, with a strong emphasis on creating AI solutions that are not only powerful but also ethical and transparent. The company recognizes the importance of building AI technologies that can be trusted by businesses and consumers alike, and it is committed to maintaining high standards of integrity and accountability in its operations, reassuring the audience about its values.

By: K. Tagura

Who we are: Funded.com is a platform that is A+ BBB accredited over 10+ years. Access our network of Angel Investors, Venture Capital or Lenders. Let us professionally write your Business Plan.

Otto, a Seattle, WA-based developer of a business travel booking platform designed for small businesses and startups. The company’s platform leverages artificial intelligence to build an intelligent and autonomous travel agent assistant for business travelers that facilitates flight and hotel bookings through natural language queries, enabling clients to streamline the travel booking process.

Otto was funded $6 million led by Madrona Ventures, with participation from Direct Travel and angel investors from across the business travel industry, this significant investment is aimed at developing an advanced AI-powered travel assistant designed to simplify and enhance the travel experience for users around the globe.

Otto aims to bridge the gap between technology and personalized travel experiences. The seed round, led by prominent venture capital firms with a keen interest in travel and AI, signals strong confidence in Otto’s vision. This funding will accelerate the development of Otto’s platform, enabling the company to bring its innovative solution to market more quickly.

In recent years, artificial intelligence has become a transformative force across numerous industries, and travel is no exception. Otto’s travel assistant is set to capitalize on this trend by offering a solution that not only helps users plan trips but also provides real-time assistance during their travels. The AI-driven platform is expected to offer personalized recommendations, seamless itinerary management, and live support, all tailored to the unique preferences and needs of each traveler.

Traveling, while exciting, often comes with its share of challenges— from booking flights and accommodations to navigating new destinations. Otto’s AI-powered assistant aims to alleviate these pain points by providing a one-stop solution that integrates various aspects of travel planning and execution. By leveraging machine learning and natural language processing, Otto intends to deliver a user experience that feels more like interacting with a knowledgeable and intuitive travel companion than using a traditional app.

Otto’s entry into the travel tech market comes at a time when the industry is ripe for innovation. As travel rebounds post-pandemic, there is a growing demand for tools that can simplify travel logistics while enhancing the overall experience. Otto’s AI-powered assistant is well-positioned to meet this demand, offering a solution that is both cutting-edge and user-centric.

The industry has reacted positively to Otto’s announcement, with many experts predicting that the company’s innovative approach could set a new standard in travel assistance. Investors are particularly excited about the potential for Otto to disrupt the travel planning process, making it more efficient and enjoyable for consumers.

Otto’s successful seed funding round marks the beginning of what promises to be an exciting journey in the travel tech industry. With its focus on leveraging AI to create a truly personalized travel assistant, Otto is poised to make a significant impact on how we plan and experience our travels in the coming years.

By: K. Tagura

Who we are: Funded.com is a platform that is A+ BBB accredited over 10+ years. Access our network of Angel Investors, Venture Capital or Lenders. Let us professionally write your Business Plan.

Amulet, a Madison, WI-based manufacturer, has developed a unique small portable electrochemical detection system. This versatile system is designed to test for common allergenic ingredients, setting it apart from traditional detection methods. The company offers a consumer brand, a signature wearable that alerts users to allergens in food, and a commercial brand that equips the industry with a versatile detection platform. This platform can identify a wide range of molecular targets, including food toxins and environmental contaminants, reassuring both food producers and consumers of its wide applicability and ease of use in targeting toxins in products at scale.

Amulet was funded $6 million by HealthX Ventures, led by HealthX Ventures, with participation from Incite Ventures, AllerFund, Mendota Venture Capital, Great Oaks Venture Capital, and individuals like Pinterest executive and Daydream founder Julie Bornstein and founder and angel investor Diede van Lamoen.

The new investment intends to advance its mission of preventing life-threatening reactions to allergens and contaminants. This significant investment underscores the growing concern around food safety, air quality, and the widespread impact of allergens on vulnerable populations.

Allergic reactions, particularly to food and environmental contaminants, are a pressing global health concern. Millions of people worldwide suffer from allergies, with many facing potentially fatal consequences from accidental exposure to allergens. Amulet aims to mitigate these risks by providing advanced solutions that detect and neutralize harmful substances before they can cause harm.

Amulet is leveraging cutting-edge technology, specifically electrochemical detection, to develop products that can detect allergens and contaminants in various environments. Their flagship product, a wearable device that can be integrated into everyday items such as clothing or accessories, is designed to monitor the user’s environment. This device can detect traces of allergens and contaminants, alerting the wearer to potential dangers and enabling them to take immediate action.

The technology developed by Amulet not only detects harmful substances but also offers insights into the presence and concentration of these threats, allowing users to make informed decisions. For instance, someone with a severe peanut allergy could be alerted to trace amounts of peanuts in a meal before consuming it, potentially preventing a severe allergic reaction.

The implications of Amulet’s technology extend beyond individuals with allergies. The company’s solutions, which can detect a wide range of contaminants, are also being designed to address broader concerns about air and water quality. By offering a proactive approach to preventing exposure to harmful contaminants, Amulet’s technology has the potential to significantly improve public health.

As Amulet continues to refine its technology and expand its product offerings, the company is not just a player but a key player in the fight against life-threatening allergic reactions and contaminant exposure. The recent funding round is a testament to the importance of their work and the potential for their innovations to save lives. With a global market for allergen and contaminant detection products, Amulet is well-positioned for significant growth.

Amulet’s relentless efforts to provide practical, real-time solutions offer a beacon of hope for millions in a world where allergens and contaminants are an ever-present threat. With the backing of investors and a clear vision for the future, Amulet is on track to revolutionize how we prevent and manage exposure to allergens and harmful substances. Ultimately, their innovative solutions hold the potential to significantly improve health outcomes for at-risk populations, instilling a sense of optimism in the fight against life-threatening allergic reactions and contaminant exposure.

By: K. Tagura

Who we are: Funded.com is a platform that is A+ BBB accredited over 10+ years. Access our network of Angel Investors, Venture Capital or Lenders. Let us professionally write your Business Plan.

Contextual AI, a San Francisco, CA-based Developer, stands out with its large language paradigm-shifting models. These models are uniquely designed to cater to enterprise needs in the field of generative artificial intelligence, a domain that has predominantly served consumers. The company’s model offers fully customizable, trustworthy, and privacy-aware artificial intelligence tools, setting it apart in the market.

Contextual AI was funded $80 million by Greycroft, with participation from Bezos Expeditions, NVentures, HSBC Ventures, and Snowflake Ventures, as well as existing strategic angel investors Bain Capital Ventures, Lightspeed Ventures, Lip-Bu Tan, Conviction, and Recall Capital.

The substantial investment of $ 80 million is not just a financial boost for Contextual AI, but a strategic move to advance AI model accuracy. This investment promises significant improvements across various applications, marking a significant step forward in the AI industry.

The $80 million infusion will primarily be directed towards enhancing the accuracy of AI models. In the rapidly evolving AI landscape, accuracy is critical in determining the effectiveness and reliability of AI-driven solutions. By improving contextual understanding, Contextual AI aims to reduce errors and increase the precision of AI outputs, instilling confidence in its strategic use of funding.

Contextual AI’s plan is to leverage the funding to develop cutting-edge technologies that can better interpret and understand the context within data. This involves sophisticated algorithms capable of discerning language, behavior, and environmental nuances. Such advancements are expected to have a transformative impact on industries ranging from healthcare and finance to customer service and autonomous vehicles, instilling a sense of optimism about the future of AI.

The investment in Contextual AI is a testament to the growing emphasis on refining AI models for better accuracy. The demand for precise and contextually aware models intensifies as AI systems become more integrated into daily operations. This funding will not only bolster Contextual AI’s capabilities but also set a new benchmark for the industry.

Looking ahead, Contextual AI is poised to play a pivotal role in shaping the future of AI technology. With enhanced model accuracy, the potential applications are vast and varied, promising to revolutionize how AI is deployed across sectors. Stakeholders and industry leaders are eagerly anticipating the innovations that Contextual AI will bring forth, backed by this significant financial support, fostering a sense of excitement about the future of AI.

The funding round marks a significant milestone for Contextual AI, propelling it towards achieving unparalleled accuracy in AI models. This development is set to drive the AI industry forward, offering more reliable and precise AI solutions for diverse applications.

By: K. Tagura

Who we are: Funded.com is a platform that is A+ BBB accredited over 10+ years. Access our network of Angel Investors, Venture Capital or Lenders. Let us professionally write your Business Plan.

DecoverAI, a Washington, DC-based pioneering AI technology company, was funded $2 million to revolutionize the legal industry with its cutting-edge AI solutions. This significant investment marks a pivotal moment for the legal sector, promising enhanced efficiency, reduced costs, and unprecedented innovation in legal practices.

For too long, the legal industry has been burdened by time-consuming processes and high operational costs. DecoverAI’s mission is to alleviate these challenges by introducing advanced AI solutions that streamline legal workflows. By harnessing the power of machine learning and natural language processing, DecoverAI’s technology can swiftly analyze vast legal documents, identify pertinent information, and provide actionable insights. This transformation empowers legal professionals to concentrate more on strategic decision-making and less on administrative tasks, fostering a sense of hope and optimism for the future of the legal industry.

The recent funding round, led by Leo Capital and with the participation of other prominent angel investors, is a testament to the confidence in DecoverAI’s vision and technology. This significant investment will be directed towards further developing the company’s AI platform, expanding its suite of legal tools, and enhancing its market reach. The strong support from these investors should reassure the audience about the company’s promising future.

The application of AI in the legal industry is not just a trend but a necessity in today’s fast-paced world. AI tools can sift through vast amounts of data quickly and accurately, identify relevant legal precedents, and even predict case outcomes based on historical data. DecoverAI’s innovative approach leverages these capabilities, offering legal professionals a competitive edge.

With this new funding, DecoverAI is poised to expand its team, invest in cutting-edge research, and forge strategic partnerships. The company plans to launch several new features within its AI platform, targeting specific pain points legal practitioners face, such as [specific features] that can significantly improve [specific aspects of legal work].

DecoverAI’s CEO Ravi Tandon expressed his optimism about the future, stating that the investment is a testament to their unwavering commitment to transforming the legal industry. They are excited to continue pushing the boundaries of what’s possible with AI, inspiring the audience with their dedication and vision.

In conclusion, DecoverAI’s recent funding milestone marks a significant step towards a more efficient, accurate, and technologically advanced legal industry. As the company continues to innovate, the legal field can expect substantial improvements in how legal services are delivered and managed.

By: K. Tagura

Who we are: Funded.com is a platform that is A+ BBB accredited over 10+ years. Access our network of Angel Investors, Venture Capital or Lenders. Let us professionally write your Business Plan.

Loyal, an Atlanta, GA-based in a significant boost to the healthcare technology sector, Loyal, a pioneering company specializing in healthcare technology systems, was funded $33.5 million in a recent funding round. This substantial investment is poised to accelerate the company’s efforts in expanding its customer base and enhancing product development.

The funding round, led by prominent venture capital firms and supported by several strategic angel investors, underscores the growing confidence in Loyal’s innovative solutions aimed at transforming patient care and hospital operations. The influx of capital will empower the company to scale its operations, introduce cutting-edge features, and reach a broader audience within the healthcare industry.

Loyal’s platform leverages advanced technologies such as artificial intelligence and machine learning to streamline various aspects of healthcare management. From patient engagement and appointment scheduling to billing and feedback collection, Loyal’s comprehensive suite of tools is designed to enhance efficiency and improve patient experiences. The new funding will enable Loyal to further refine these tools and develop new capabilities that address emerging needs in the healthcare landscape.

Chad Mallory, CEO of Loyal said, securing this funding marks a pivotal moment for Loyal. With the additional resources, they can accelerate their mission to deliver transformative solutions that empower healthcare providers and improve patient outcomes. They are committed to driving innovation and setting new standards in the industry.

The healthcare sector is witnessing a rapid digital transformation, driven by the need for more efficient and patient-centric solutions. Loyal’s technology plays a crucial role in this evolution, offering healthcare providers the tools they need to navigate the complexities of modern healthcare delivery. By expanding its customer base, Loyal aims to bring its innovative solutions to a wider array of healthcare institutions, from small clinics to large hospital networks.

Investors in this funding round highlighted Loyal’s potential to make a significant impact on the healthcare industry. Loyal’s commitment to innovation and its track record of success make it a standout player in the healthcare technology space.

As Loyal embarks on this new chapter, the healthcare community eagerly anticipates the advancements that will emerge from the company’s enhanced capabilities. With a strong foundation and a clear vision for the future, Loyal is well-positioned to drive meaningful change in the healthcare technology landscape.

By: K. Tagura

Who we are: Funded.com is a platform that is A+ BBB accredited over 10+ years. Access our network of Angel Investors, Venture Capital or Lenders. Let us professionally write your Business Plan.

Jacobi Robotics, a Berkeley, CA-based developer of robotics software designed to accelerate the development time of robot arm applications, and make industrial robot arms safe, flexible, and more productive. The company’s platform provides proprietary software building blocks such as motion planning, visualization, and perception, enabling businesses to implement robots in a wide range of applications.

Jacobi Robotics was funded $5 million led by Moxxie Ventures with participation from Foothill Ventures, Humba Ventures, The House Fund and existing investors Swift Ventures, Berkeley SkyDeck Fund, LDV Partners, strategic angel investors of Courtyard Ventures. This infusion of capital is set to propel Jacobi Robotics’ research and development efforts, enabling them to enhance their motion planning algorithms and expand their market reach.

Jacobi Robotics has been at the forefront of developing sophisticated motion planning technology designed to improve the efficiency and precision of robotic movements. Their technology is pivotal for applications across various industries, including manufacturing, healthcare, logistics, and autonomous vehicles.

The company’s technology focuses on enabling robots to navigate complex environments with minimal human intervention. By improving pathfinding and obstacle avoidance capabilities, Jacobi Robotics aims to enhance the operational efficiency of automated systems.

In the manufacturing sector, their technology promises to streamline assembly lines, reducing downtime and increasing productivity. In healthcare, it can assist in the precise control of surgical robots, leading to better patient outcomes. Additionally, in logistics, their solutions can optimize the navigation of automated warehouses, facilitating faster and more accurate order fulfillment.

With the new funding, Jacobi Robotics plans to expand its team, investing in top-tier engineering talent and strengthening its partnerships with leading tech companies. The company is also looking to explore new markets and applications for its technology, broadening its impact across the global robotics landscape.

Jacobi Robotics’ recent funding success underscores the growing importance of advanced motion planning technology in the robotics field. As they continue to push the boundaries of what is possible, the company is well-positioned to lead the next wave of innovation in robotic automation.

By: K. Tagura

Author statement:

Who we are: Funded.com is a platform that is A+ BBB accredited over 10+ years. Access our network of Angel Investors, Venture Capital or Lenders. Let us professionally write your Business Plan.